Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 9/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 5/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.39 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 7/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16834463 | 0.76 | — | — | |
| SCHEMBL6597600 | 0.76 | CYP3A4 (0.39) | CYP3A4CYP2A6ALOX15MEN1KMT2A | |
| SCHEMBL10066877 | 0.74 | CYP3A4 (0.54) | CYP3A4CYP2A6ALOX15MEN1KMT2A | |
| SCHEMBL28614447 | 0.72 | CYP3A4 (0.52) | CYP3A4CYP2A6ALOX15MEN1KMT2A | |
| SCHEMBL18429869 | 0.72 | CYP3A4 (0.42) | CYP3A4CYP2A6ALOX15MEN1KMT2A | |
| SCHEMBL29401947 | 0.71 | CYP3A4 (0.55) | CYP3A4CYP2A6ALOX15MEN1KMT2A | |
| SCHEMBL117382 | 0.71 | CYP3A4 (0.55) | CYP3A4CYP2A6ALOX15MEN1KMT2A | |
| SCHEMBL4675590 | 0.69 | MAPT (0.49) | CYP3A4CYP2A6ALOX15MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL6446846 | 0.69 | CYP3A4 (0.53) | CYP3A4CYP2A6ALOX15MEN1KMT2A | |
| SCHEMBL16923125 | 0.69 | CYP3A4 (0.48) | CYP3A4CYP2A6ALOX15MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9962377-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2018-05-08 | — | — | US | disclosed |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2016-09-29 | — | — | US | disclosed |
| US-9387205-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2016-07-12 | — | — | US | disclosed |
| US-20150352096-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-10 | — | — | US | disclosed |
| US-9149479-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2015-10-06 | — | — | US | disclosed |
| US-20150119389-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-04-30 | — | — | US | disclosed |
| US-8883818-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-11-11 | — | — | US | disclosed |
| EP-2589599-B1 | Novel hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2014-06-25 | — | — | EP | disclosed |
| US-20140073636-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | TAKEDA GMBH (DE) | 2014-03-13 | — | — | US | disclosed |
| US-8455653-B2 | Hydroxy-6-heteroarylphenanthridines and their use as PDE4 inhibitors | TAKEDA GMBH (DE) | 2013-06-04 | — | — | US | disclosed |
| EP-1723135-A1 | NOVEL HYDROXY-6-HEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | Altana Pharma AG (DE) | 2006-11-22 | — | — | EP | disclosed |
| WO-2006082185-A1 | NOVEL 6-PYRIDYLPHENANTHRIDINES | NYCOMED GMBH (DE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2005085225-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | ALTANA PHARMA AG (DE) | 2005-09-15 | — | — | WO | disclosed |
| US-6900209-B2 | Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition | MERCK SHARP & DOHME LTD. | 2005-05-31 | — | — | US | disclosed |
| US-20040043982-A1 | Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition | MERCK SHARP & DOHME LTD. (GB) | 2004-03-04 | — | — | US | disclosed |
| US-6613766-B1 | Compounds such as 3-(5-methylisoxazol-3-yl)-5-(2-pyridyl-methyloxy)-1,2,3a,4,6 -pentaazacyclopenta(a)naphthalene, having high receptivity for the inhibitory neurotransmitter, gamma-aminobutyric acid (GABA); learning enhancement | MERCK SHARP & DOHME LTD. | 2003-09-02 | — | — | US | disclosed |
| EP-0986562-B1 | SUBSTITUTED 1,2,4-TRIAZOLO 3,4-A]PHTHALAZINE DERIVATIVES AS GABA ALPHA 5 LIGANDS | MERCK SHARP & DOHME (GB) | 2002-08-07 | — | — | EP | disclosed |
| US-6313125-B1 | FOR ENHANCING COGNITION IN PATIENTS SUFFERING FROM ALZHEIMER'S DISEASE | MERCK SHARP & DOHME LTD. (GB) | 2001-11-06 | — | — | US | disclosed |
| US-6310203-B1 | Precursor compounds to substituted 1,2,4-triazolo[3,4,-a]phathalazine GABA alpha 5 ligands | MERCK SHARPE & DOHME LIMITED (GB) | 2001-10-30 | — | — | US | disclosed |
| US-6200975-B1 | FOR COGNITION ENHANCEMENT THERAPY | MERCK SHARP & DOHME LIMITED (GB) | 2001-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150352096-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | CYP3A4 26/4885CYP2A6 53/4885ALOX15 2613/4885 |
| US-20140073636-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE12 | CYP3A4 26/4885CYP2A6 53/4885ALOX15 2613/4885 |
| US-20040043982-A1 | Nitrogen substituted 1,2,4-triazolo[3,4-a]phthalazine derivatives for enhancing cognition | PSEN1, BDNF, H1-5 | CYP3A4 2494/4885CYP2A6 2808/4885ALOX15 479/4885 |
| US-20150119389-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE4B, PDE4C | CYP3A4 31/4885CYP2A6 63/4885ALOX15 2937/4885 |
| US-20160279120-A1 | NOVEL HYDROXY-6-HETEROARYLPHENANTHRIDINES AND THEIR USE AS PDE4 INHIBITORS | PDE4A, PDE12, PDE4B | CYP3A4 24/4885CYP2A6 38/4885ALOX15 2115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.